In general, canonical activation of HH-GLI signaling occurs in cancers with mutations in PTCH1 and SMO, such as BCC and SHH-type medulloblastoma, most of which are sensitive to SMO antagonists. This evidence concerns the gene GLI1 and skin basal cell carcinoma.